In late April 2026, analysts highlighted expectations for higher year-over-year earnings and revenue at CRISPR Therapeutics ahead of its March-quarter report, alongside strong launch metrics for ...

Morningstar, Inc. (NASDAQ: MORN), a leading provider of independent investment insights, has reached a new milestone in its previously completed acquisition of the Center for Research in Security ...

In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $50.71, marking a -2.59% move from the previous day. The stock's performance was behind the S&P 500's daily loss of 0.04%.

In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $52.06, marking a +2.1% move from the previous day. This change outpaced the S&P 500's 0.49% loss on the day. Elsewhere, the Dow ...

View CRISPR Therapeutics AG CRSP stock quote prices, financial information, real-time forecasts, and company news from CNN.

CRISPR Therapeutics (CRSP) stock dropped 11% after missing Q1 estimates badly. Regeneron's free gene therapy approval adds ...

Tue, March 17, 2026 at 4:16 PM UTC The catalyst behind Piper Sandler's revised target is a freshly issued $600M convertible note due March 2031, convertible at $76.56 per share with an effective ...

The average one-year price target for CRISPR Therapeutics (NasdaqGM:CRSP) has been revised to $82.91 / share. This is an increase of 14.61% from the prior estimate of $72.34 dated January 11, 2026.

We recently published These 10 Stocks Surprisingly Lead Gains While Wall Street Naps. CRISPR Therapeutics AG (NASDAQ:CRSP) is one of this week’s top performers. CRISPR Therapeutics soared by 18.22 ...